Intellia Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that uses CRISPR gene-editing technology to develop medicines for genetic diseases. Founded in 2014 with Nobel Prize-winning scientist Jennifer Doudna as a co-founder, it made history in 2021 by delivering the first-ever CRISPR edit inside a human body, targeting a protein that causes a rare heart condition. Its name blends "intelligence" with a biotech-style suffix.
Granted 749.3K · Sold 321.5K
Granted 5.2K
Granted 34.6K · Bought 150.0K
Granted 174.8K · Sold 13.8K
Granted 155.3K · Sold 29.6K
Granted 37.1K · Bought 100.0K
Granted 76.8K · Sold 8.5K
Granted 149.6K · Sold 39.5K
Granted 116.8K · Sold 32.8K
Granted 175.4K · Sold 118.6K
Granted 49.1K · Sold 10.7K
Granted 95.7K · Sold 41.3K
Granted 72.1K · Sold 12.2K
Granted 34.6K
Granted 39.3K · Sold 2.9K
Granted 34.6K · Sold 1.5K
Granted 34.6K · Sold 3.1K
Granted 32.6K
Granted 5.2K
Granted 22.1K · Sold 12.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leonard John MPresident and CEO, Director · 37 transactions | +53.4% | 1.21M | 749.3K | — | 321.5K |
| Formela Jean FrancoisDirector · 1 transaction | +0.6% | 827.2Kas of Jun 2022 | 5.2K | — | — |
| Cohen Fred EDirector · 6 transactions | +10246.4% | 216.7K | 34.6K | 150.0K | — |
| Dulac Edward J IIIEVP, Chief Financial Officer · 5 transactions | — | 161.0K | 174.8K | — | 13.8K |
| Basta JamesEVP, General Counsel · 13 transactions | — | 156.8K | 155.3K | — | 29.6K |
| Chase William JDirector · 6 transactions | — | 143.9K | 37.1K | 100.0K | — |
| Schultes Birgit CEVP, Chief Scientific Officer · 4 transactions | — | 137.7K | 76.8K | — | 8.5K |
| Lebwohl DavidEVP, Chief Medical Officer · 31 transactions | +16485.6% | 131.2K | 149.6K | — | 39.5K |
| Clark ElianaEVP, Chief Technical Officer · 22 transactions | — | 93.9K | 116.8K | — | 32.8K |
| Sepp-Lorenzino LauraEVP, Chief Scientific Officer · 23 transactions | +284.9% | 77.4Kas of Jan 2025 | 175.4K | — | 118.6K |
| Dube Michael PVP, Chief Accounting Officer · 8 transactions | — | 69.5K | 49.1K | — | 10.7K |
| Goddard GlennEVP, Chief Financial Officer · 20 transactions | — | 69.2Kas of Mar 2024 | 95.7K | — | 41.3K |
| Hicks DerekEVP, Chief Business Officer · 6 transactions | — | 59.9Kas of Jan 2025 | 72.1K | — | 12.2K |
| Keresty GeorgiaDirector · 5 transactions | +529.7% | 41.1K | 34.6K | — | — |
| Bhanji MunaDirector · 11 transactions | — | 36.4K | 39.3K | — | 2.9K |
| Verwiel FrankDirector · 6 transactions | +1578.5% | 35.1K | 34.6K | — | 1.5K |
| Goodman JesseDirector · 7 transactions | +1502.6% | 33.6K | 34.6K | — | 3.1K |
| Goff BrianDirector · 3 transactions | — | 32.6K | 32.6K | — | — |
| Dorsa CarolineDirector · 1 transaction | +506.5% | 12.7Kas of Jun 2022 | 5.2K | — | — |
| Crowley John FDirector · 10 transactions | +459.5% | 11.7Kas of Jun 2023 | 22.1K | — | 12.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -398.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.